Express Pharma

Penbraya approval sparks shift to pentavalent meningococcal vaccines in US: GlobalData

GSK is also in the process of developing a pentavalent vaccine, and positive Phase III data were announced earlier this year. GlobalData projects the collective revenue for these two pentavalent vaccines to reach approximately $555 million in the US by 2029

0 142